<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463590</url>
  </required_header>
  <id_info>
    <org_study_id>Habenula DBS for OCD</org_study_id>
    <nct_id>NCT03463590</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation of the Bilateral Habenula for Treatment-Refractory Obsessive-Compulsive Disorder</brief_title>
  <official_title>Deep Brain Stimulation of the Bilateral Habenula for Treatment-Refractory Obsessive-Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deep brain stimulation (DBS) offers an effective and safe treatment for patients with
      debilitating, otherwise treatment-refractory obsessive-compulsive disorder(OCD). Although
      several target areas for DBS have been used for OCD, such as the ventral capsule/ventral
      striatum and the subthalamic nucleus, not all patients show a clinical response, varying from
      10% to 61.5%. Exploring new DBS targets may be a key approach to improve this situation. The
      habenula is an evolutionarily conserved structure playing an important role in depression,
      punishment avoiding, reward, addiction, pain and circadian rhythms. The habenula can be
      considered a promising target for OCD treatment based on the following hypotheses and
      clinical observations.

        1. The lateral habenula DBS has significant clinical antidepressant effects.

        2. The habenula plays an important role in the regulation of dopamine and serotonin
           systems.

        3. Selective serotonin reuptake inhibitors, the first line treatment for OCD, are commonly
           used to treat clinical depression.

        4. The habenula serves as a 'negative reward center' that mediates or moderates stress,
           negative emotions and thoughts, aversive learning, and goal-directed behavior, which are
           core clinical symptoms and signs of OCD.

        5. In our hospital, DBS of the habenula produced a significant improvement in OCD symptoms
           in one patient who failed to respond to other treatments, including capsulotomy either
           alone or in combination combined with cingulumotomy.

      These theoretical and clinical considerations indicate that the habenula can be seen as a
      promising DBS target for OCD treatment. This study is focused on the effectiveness of
      bilateral DBS of the habenula for patients with treatment-refractory OCD. Furthermore, the
      study is aimed at exploring the influence of DBS of the habenula on brain activity and
      cognition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects will receive bilateral surgical implantation of DBS system</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Y-BOCSII Score</measure>
    <time_frame>Baseline (preoperative),1 month, 3 months,6 months, 9 months</time_frame>
    <description>The score of the scale ranges from 0 to 50</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in OCI-R Score</measure>
    <time_frame>Baseline (preoperative),1 month, 3 months,6 months, 9 months</time_frame>
    <description>The score of the scale ranges from 0 to 72</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in the Hamilton Depression Scale(HAMD-17)</measure>
    <time_frame>Baseline（preoperative）,1 month, 3 months, 6 months,9 months</time_frame>
    <description>The score of the scale ranges from 0 to 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the Hamilton Anxiety Scale(HAMA-14)</measure>
    <time_frame>Baseline（preoperative）,1 month, 3 months, 6 months,9 months</time_frame>
    <description>The score of the scale ranges from 0 to 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in FMRI signal</measure>
    <time_frame>Baseline（preoperative）,3 month, 6 months, 9 months</time_frame>
    <description>The FMRI signal is to estimate Blood Oxygenation Level Dependent (BOLD) and connectivity of brain areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in World Health Organization Quality of Life-BREF(WHO-BREF)</measure>
    <time_frame>Baseline（preoperative）,1 month, 3 months,6 months,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes the MOS item short from health survey (SF-36)</measure>
    <time_frame>Baseline（preoperative）,1 month, 3 months,6 months,9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological measures(Scores of cogstate battery)</measure>
    <time_frame>Baseline（preoperative）,1 month, 3months,6months,9months</time_frame>
    <description>Neuropsychological measures contains six tasks which are detection task, identification task, one card learning task, one back task, Groton maze learning task, set-shifting task</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilateral surgical implantation of DBS system to habenula</intervention_name>
    <description>The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.</description>
    <arm_group_label>DBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as having primary OCD according to DSM-IV criteria using the Structured
             Clinical Interview for DSM-IV Axis I disorders;

          -  YBOCSII score ≥31；

          -  Duration ≥2 years；

          -  Refractoriness to therapy was defined as no response or insufficient response
             following at least 2 treatments with adequate trials or intolerance to two or three
             selective serotonin transporter inhibitors (SSRIs) and clomipramine, augmentation
             strategies (antipsychotics) and cognitive behavioral therapy.

          -  Capacity to provide informed consent (understanding of the study purpose and methods.

        Exclusion Criteria:

          -  Except for those with major depressive disorder and mild anxiety disorders, patients
             with clinically significant comorbid DSM-IV diagnoses (such as schizophrenia, bipolar
             II disorder, alcohol or substance abuse in the last 6 months, current tic disorder, or
             body dysmorphic disorder)

          -  Patients with severe personality disorders, assessed using the Structured Clinical
             Interview for DSM-IV Axis II disorders.

          -  Serious and unstable organic diseases (e.g. unstable coronal heart disease);

          -  Pregnancy and/or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yingying Zhang, MSc</last_name>
    <phone>+086-17602137369</phone>
    <email>zhyy019@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital Functional Neurosurgery</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chencheng Zhang, MD</last_name>
      <phone>+086-18217122884</phone>
      <email>i@cczhang.org</email>
    </contact>
    <contact_backup>
      <last_name>Yingying Zhang, MSc</last_name>
      <phone>+086-17602137369</phone>
      <email>zhyy019@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Alonso P, Cuadras D, Gabriëls L, Denys D, Goodman W, Greenberg BD, Jimenez-Ponce F, Kuhn J, Lenartz D, Mallet L, Nuttin B, Real E, Segalas C, Schuurman R, du Montcel ST, Menchon JM. Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response. PLoS One. 2015 Jul 24;10(7):e0133591. doi: 10.1371/journal.pone.0133591. eCollection 2015.</citation>
    <PMID>26208305</PMID>
  </reference>
  <reference>
    <citation>Kohl S, Baldermann JC. Progress and challenges in deep brain stimulation for obsessive-compulsive disorder. Pharmacol Ther. 2018 Jan 31. pii: S0163-7258(18)30018-4. doi: 10.1016/j.pharmthera.2018.01.011. [Epub ahead of print] Review.</citation>
    <PMID>29406245</PMID>
  </reference>
  <reference>
    <citation>Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017 Apr 4;317(13):1358-1367. doi: 10.1001/jama.2017.2200. Review.</citation>
    <PMID>28384832</PMID>
  </reference>
  <reference>
    <citation>Batalla A, Homberg JR, Lipina TV, Sescousse G, Luijten M, Ivanova SA, Schellekens AFA, Loonen AJM. The role of the habenula in the transition from reward to misery in substance use and mood disorders. Neurosci Biobehav Rev. 2017 Sep;80:276-285. doi: 10.1016/j.neubiorev.2017.03.019. Epub 2017 May 30. Review.</citation>
    <PMID>28576510</PMID>
  </reference>
  <reference>
    <citation>Fakhoury M. The habenula in psychiatric disorders: More than three decades of translational investigation. Neurosci Biobehav Rev. 2017 Dec;83:721-735. doi: 10.1016/j.neubiorev.2017.02.010. Epub 2017 Feb 13. Review.</citation>
    <PMID>28223096</PMID>
  </reference>
  <reference>
    <citation>Antolin-Fontes B, Ables JL, Görlich A, Ibañez-Tallon I. The habenulo-interpeduncular pathway in nicotine aversion and withdrawal. Neuropharmacology. 2015 Sep;96(Pt B):213-22. doi: 10.1016/j.neuropharm.2014.11.019. Epub 2014 Dec 2. Review.</citation>
    <PMID>25476971</PMID>
  </reference>
  <reference>
    <citation>Boulos LJ, Darcq E, Kieffer BL. Translating the Habenula-From Rodents to Humans. Biol Psychiatry. 2017 Feb 15;81(4):296-305. doi: 10.1016/j.biopsych.2016.06.003. Epub 2016 Jun 7. Review.</citation>
    <PMID>27527822</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Bomin Sun</investigator_full_name>
    <investigator_title>Director of the Department of Functional Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Habenula</keyword>
  <keyword>Obsessive-Compulsive Disorder</keyword>
  <keyword>Deep brain stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

